Lunesta Overdose & Accidental Excess Dose: Clinical Management Guide

How Eszopiclone Works: The Mechanism Behind Its Toxicity

Eszopiclone is the active S(+) enantiomer of racemic zopiclone. It binds the benzodiazepine recognition site on GABA-A receptors, increasing chloride ion influx and producing sedation, anxiolysis, and muscle relaxation. This mechanism explains why overdose is dangerous: as receptor potentiation deepens with dose, CNS depression can extend from sedation into respiratory suppression.

GABA-A Receptor Pharmacology

GABA-A receptors are ligand-gated chloride channels distributed throughout the brain, spinal cord, and brainstem respiratory centers. Eszopiclone is a positive allosteric modulator, meaning it does not activate the receptor alone but amplifies the effect of endogenous GABA. At therapeutic doses (1 to 3 mg), this produces sleep onset within roughly 15 to 30 minutes. At supratherapeutic doses, the same mechanism can suppress brainstem respiratory drive.

Eszopiclone shares its receptor binding site with classic benzodiazepines, which is why the clinical toxidrome at high doses closely resembles benzodiazepine poisoning, and why flumazenil, a benzodiazepine-site antagonist, can partially reverse it. Comparative pharmacology work on nonbenzodiazepine hypnotics versus benzodiazepine-site agonists is generally understood to support this shared mechanism. The exact degree of receptor affinity overlap between eszopiclone and any specific benzodiazepine has not been independently confirmed for this article and should be treated as a general pharmacologic pattern rather than a precise equivalence.

Pharmacokinetics Relevant to Overdose

• Peak plasma concentration (Tmax): approximately 1 hour after oral ingestion
• Half-life: approximately 6 hours in healthy adults; extended to roughly 9 hours in patients older than 65
• Protein binding: roughly 52 to 59%, which limits how much dialysis can remove
• Metabolism: hepatic metabolism via CYP3A4 and CYP2E1 to inactive and active metabolites
• Renal excretion: less than 10% unchanged drug in urine

The roughly 6-hour half-life means a patient who takes 30 mg (ten times the maximum therapeutic dose) at midnight can still have clinically significant plasma levels the next morning. Concurrent CYP3A4 inhibitors such as certain azole antifungals, macrolide antibiotics, or protease inhibitors can meaningfully raise eszopiclone plasma exposure, turning a moderate excess dose into a more severe one. The FDA prescribing information for eszopiclone describes this drug interaction and its magnitude with strong CYP3A4 inhibitors. Anyone starting a new interacting medication should confirm the specific interaction and any dose adjustment with a pharmacist or prescriber rather than relying on a single reported figure.

What Constitutes an Overdose

There is no single, universally agreed milligram threshold that defines eszopiclone overdose. The FDA-approved maximum dose is 3 mg per night for adults without hepatic impairment. Any ingestion substantially above that warrants clinical evaluation, and the threshold for concern is lower in children, older adults, patients with liver disease, and patients on interacting medications.

Accidental Excess Doses

Accidental excess doses are the most common presentation seen clinically. They tend to follow a few predictable patterns:

1. Dose confusion. A patient fills a new prescription at a different strength than before and takes their usual number of tablets without recalculating the milligram total.
2. Night-time re-dosing. Eszopiclone's amnesia effect can cause a patient to forget they already took a dose and take a second one. This behavior is a recognized risk with this drug class.
3. Pediatric ingestion. A child finds an unsecured bottle. Lower body weight and immature hepatic metabolism mean even a single tablet may cause clinically significant CNS depression in a young child.
4. Drug interaction amplification. The patient adds an over-the-counter antihistamine, an opioid, or alcohol, multiplying the CNS depressant effect without increasing the eszopiclone dose itself.

Intentional Overdose

Intentional ingestion represents a smaller share of eszopiclone exposures but tends to carry higher severity, largely because co-ingestion of other CNS depressants is common in that setting. Sedative-hypnotic medications are frequently involved in poison center exposure reports, and outcomes worsen substantially when other sedating substances are involved.

Signs and Symptoms of Eszopiclone Overdose

Symptoms generally follow a dose-response pattern. A mild excess dose may cause little more than prolonged sleep. A severe overdose, particularly with co-ingested CNS depressants, can cause respiratory failure.

Mild to Moderate Toxicity

• Excessive sedation or sleep that extends well beyond the intended 7 to 8 hours
• Anterograde amnesia on waking
• Ataxia, stumbling, or an inability to walk safely
• Slurred speech
• Confusion or disorientation, sometimes mistaken for an acute change in an older adult
• Double vision

These features typically resolve with supportive monitoring and time. A patient who is arousable, protecting their airway, and maintaining oxygen saturation above 94% on room air generally does not require intubation.

Severe Toxicity

• Unarousable deep sedation
• Respiratory depression (breathing rate under 10 per minute or oxygen saturation under 90%)
• Hypotension (systolic blood pressure under 90 mmHg), usually from vasodilation
• Low body temperature
• Aspiration, particularly if vomiting occurred while unconscious

Co-ingestion of opioids, alcohol, or other sedatives is a consistent and well-documented driver of worse outcomes in Z-drug and benzodiazepine overdose, including a higher risk of death, more so than the eszopiclone dose alone. An earlier version of this article cited a specific fourfold mortality increase from a named 2012 review; that citation could not be verified against the source list for this draft and has been removed. The general point, that co-ingestants matter more than the isolated eszopiclone dose, remains well supported by toxicology teaching and should be confirmed against current literature before this section receives clinical sign-off.

Emergency Management: Step-by-Step

The following reflects general emergency toxicology practice for sedative-hypnotic overdose and should be treated as background education, not a substitute for a poison control consult or institutional protocol.

Step 1: Call Poison Control Immediately

In the US, the Poison Help line (1-800-222-1222) operates 24 hours a day. Toxicologists on the line can guide a lay responder before EMS arrives and can advise clinicians on management decisions. Do not wait for symptoms to develop before calling.

Step 2: Stabilize Airway, Breathing, Circulation

Airway, breathing, and circulation remain the priority. Position an unconscious but breathing patient in the recovery position. Give supplemental oxygen. Establish IV access. Use continuous pulse oximetry, cardiac monitoring, and frequent blood pressure checks in severe presentations.

Intubation is indicated if the patient cannot protect the airway, cannot maintain oxygen saturation above 90% on supplemental oxygen, or has a respiratory rate below 8 breaths per minute.

Step 3: Assess for Co-Ingestants

Order a comprehensive metabolic panel, acetaminophen level, salicylate level, and ethanol level in intentional overdose cases. Order a urine drug screen. Quantitative levels for benzodiazepines, opioids, or other sedatives change management; a patient who ingested eszopiclone plus an opioid may improve respiratory status after naloxone, which addresses the opioid component only.

Step 4: Gastrointestinal Decontamination

Activated charcoal may be considered if the patient presents within roughly an hour of ingestion and has a protected airway. Because eszopiclone causes rapid CNS depression, the window for safe charcoal administration is narrow. Position statements from clinical toxicology societies on gastric lavage have generally found no outcome benefit from routine lavage in sedative-hypnotic overdose, a stance widely applied to this drug class.

Step 5: Consider Flumazenil Selectively

Flumazenil is a competitive GABA-A benzodiazepine-site antagonist. It can reverse sedation from eszopiclone through the same receptor mechanism it reverses benzodiazepine sedation. Routine use is not recommended in mixed or unknown overdose for several reasons:

• It may precipitate acute withdrawal seizures in patients who are chronically dependent on benzodiazepines or Z-drugs.
• Its half-life, roughly an hour, is far shorter than eszopiclone's, so re-sedation is likely once flumazenil wears off.
• It does not reverse respiratory depression caused by co-ingested opioids, alcohol, or other drugs.

When used, flumazenil is typically dosed and titrated by an emergency clinician with seizure precautions in place. Clinical reviews on flumazenil's risk-benefit profile have generally suggested it is most appropriate for iatrogenic procedural over-sedation rather than undifferentiated overdose presentations.

Step 6: Supportive Care and Observation

Most patients with isolated eszopiclone overdose improve within 6 to 12 hours with supportive care alone. Monitored observation for at least several hours is appropriate for symptomatic patients, with the length individualized to dose, co-ingestants, and patient factors such as age and liver function. IV fluids address hypotension in most cases; vasopressors are rarely needed for isolated Z-drug overdose.

Specific Populations at Elevated Risk

Older Adults

The FDA-labeled starting dose for patients 65 and older is limited to 1 mg because of reduced hepatic clearance, and the average half-life extends from about 6 hours to about 9 hours in this population. An older adult who doubles their prescribed dose faces disproportionately prolonged sedation. Hypnotic medications, including Z-drugs, are separately associated in observational research with increased fall and fracture risk in older adults; anyone prescribing or monitoring eszopiclone in this population should weigh that risk explicitly, and a specific effect size for eszopiclone should be confirmed against current literature rather than assumed.

Patients with Hepatic Impairment

According to the FDA prescribing information, severe hepatic impairment meaningfully reduces eszopiclone clearance, and the labeled maximum dose in severe hepatic impairment is 2 mg, which can still accumulate with repeated nightly use. An accidental double dose in a patient with cirrhosis is clinically closer to a much higher dose in a healthy adult.

Children

Eszopiclone has no FDA-approved pediatric indication. A toddler who ingests a single adult tablet may develop deep sedation requiring hospital admission. Management follows the same airway-breathing-circulation framework as adult overdose, with weight-based dosing for any medication used, including flumazenil if a clinician elects to use it.

Patients on CYP3A4 Inhibitors

As noted under pharmacokinetics, drugs such as certain azole antifungals, macrolide antibiotics, and protease inhibitors can raise eszopiclone plasma concentrations. A patient who starts one of these medications without adjusting their eszopiclone dose is effectively taking a higher nightly dose than prescribed.

What the Long-Term Safety Trial Shows

A randomized, double-blind, placebo-controlled trial of eszopiclone 3 mg nightly versus placebo over 6 months (Krystal et al., published in Sleep, 2003) is one of the longest placebo-controlled trials conducted for an approved hypnotic. The trial reported statistically significant, sustained improvement in sleep onset and sleep maintenance measures across the 6-month period compared with placebo, without evidence of tolerance. The most commonly reported adverse effects in the trial included an unpleasant taste, dizziness, and daytime sedation; exact rates are not restated here because they could not be independently reconfirmed for this draft, and should be pulled directly from the published trial before publication if precise figures are needed.

This trial is also why eszopiclone is prescribed at 1 to 3 mg rather than higher: efficacy did not continue to improve above 3 mg in dose-ranging work, while adverse effects did. That is the clinical rationale for treating any dose meaningfully above 3 mg as unnecessary and as carrying added risk without added benefit.

The American Academy of Sleep Medicine's 2017 clinical practice guideline supports pharmacologic treatment for sleep onset and sleep maintenance insomnia in appropriately selected adults, with monitoring for adverse events, and recommends prescribing the lowest effective dose. That guideline is generally cited as the basis for treating dose-dependent over-sedation as the primary safety concern with this drug class.

Decision Framework: What To Do If Too Much Was Taken

This is general educational guidance, not a diagnostic tool or a substitute for a poison control consult or emergency evaluation. When any of the exceptions below apply, treat the situation as more urgent than the symptoms alone might suggest.

Exceptions that move a case out of the "home monitoring" tier even if the person looks fine right now:

• Age 65 or older, because clearance is slower and sedation can run longer and deeper than expected
• Known liver disease, because eszopiclone can accumulate well beyond a healthy adult's expected course
• A new interacting medication started recently, such as certain antifungals, certain antibiotics, or HIV protease inhibitors
• Any alcohol, opioid, or other sedating medication taken the same night
• Pregnancy, or the person lives alone with no one available to check on them overnight
• A child of any age, at any dose

Why the timing matters: eszopiclone's half-life is roughly 6 hours in a healthy adult and roughly 9 hours in someone over 65, so a decision that looks fine in the first hour can look different by hour 6, when a second dip in alertness is possible. When in doubt, calling 911 is never the wrong call; EMS can stand down if it turns out not to be needed, and that decision cannot be reversed in the other direction.

Preventing Accidental Excess Doses

Prevention is clinically actionable and easy to overlook in a routine prescribing encounter.

Counseling Points for Every Prescription

• Take eszopiclone only immediately before bed, with at least 7 to 8 hours available before the planned wake time.
• Never take a second dose if you cannot remember whether you took the first one. Skip the dose instead.
• Do not combine with alcohol, opioids, antihistamines, muscle relaxants, or any other CNS depressant without explicit approval from a prescriber.
• Store the medication somewhere inaccessible to children and to yourself during any nighttime sleepwalking-type behavior, which is a documented effect with this drug class.
• If you start a new antibiotic, antifungal, or HIV medication, ask a pharmacist whether it affects eszopiclone before taking your usual dose.

Prescribing Safeguards

Prescribers can reduce overdose risk by dispensing the smallest appropriate quantity, avoiding automatic refills on a Schedule IV sedative, starting patients 65 and older at 1 mg regardless of perceived health status, documenting a discussion of overdose risk, and checking a prescription drug monitoring program before each new prescription to identify overlapping CNS depressant prescriptions from other providers. A smaller supply at a time when monitoring is limited is a straightforward way to reduce the size of a possible accidental overdose.

When to Call 911 vs. Poison Control

Call 911 immediately if the person:

• Cannot be awakened by voice or a sternal rub
• Is breathing fewer than 8 times per minute or making gurgling sounds
• Has blue lips or fingertips
• Is having a seizure
• Is vomiting while unconscious

Call Poison Control (1-800-222-1222) if the person:

• Is awake but confused after taking more than their prescribed dose
• Took an extra tablet and is uncertain whether it is dangerous
• Is a child who found and may have ingested an adult's prescription

If in doubt, calling 911 is never wrong. EMS can be stood down if Poison Control determines it is not needed; the reverse is not possible.